Recon: Sanofi eyes $1.1B investment in French manufacturing sites; Shionogi COVID treatment misses endpoint in Phase 3 trial
ReconJason Scott
Biologics/ biosimilars/ vaccinesEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/PolicyUnited States